Sentence examples for score for prostate from inspiring English sources

Pathology studies of pancreatic cancer have examined a scoring system based on grade, similar to Gleason score for prostate cancer, and have shown good predictive ability as well as reproducibility.

In brief, each breast or ovarian cancer scores according to the age at onset and cancer site (ovarian cancer scores higher than breast cancer), with a small additional score for prostate and pancreatic cancers in BRCA2.

It plays an important role in prognostic score for a variety of tumors, such as Gleason score for prostate cancer [ 6], Child-pugh classification for hepatocellular carcinoma [ 7], SBR, WHO score for breast cancer [ 8], but the prognostic effect of histopathology has never been reported in gastric cancer.

Currently, most established cancer types and cancer grading systems (such as Gleason score for prostate cancers [ 8] and WHO grades for tumours of the central nervous system [ 9]) are not even based on genetic markers but instead on clinical parameters and phenotypic observations.

The pathologist Donald Gleason, who invented Gleason scoring for prostate tumors, wanted to rename a very common tumor — the so-called Gleason 3 + 3 — "adenosis" instead of cancer, Dr. Brawley said.

Further assessment of the network for biomarker discovery and its assignment to disease entities in MetaCore™ platform significantly scored for prostate cancer.

We evaluated two previously published clinical risk scores for prostate cancer mortality in patients managed conservatively.

SVM classifier resulted in a slightly higher sensitivity but a lower specificity than LDA method for final Gleason score prediction for prostate cancer for this limited patient population.

Our results showed the item stabilities held across the three different time periods, satisfying an important measurement property for making meaningful HRQOL score comparison for prostate cancer patients in a longitudinal study [ 43].

The average absolute Z score for known prostate cancer genes was 2.06 ± 0.12, and the overall average score for the third level of the meta-analysis was 1.53 ± 0.01.

Here we present a needle biopsy-based validation study of both the CCP score alone and as part of a prespecified linear combination with standard clinical variables (combined clinical-cell-cycle-risk (CCR) score) for predicting prostate cancer death in a contemporary cohort of men with clinically localised disease who were initially managed conservatively.